AG˹ٷ

STOCK TITAN

[Form 4] SANUWAVE Health, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

On 30 June 2025, SANUWAVE Health, Inc. (ticker: SNWV) granted Director Jeffrey Blizard a fully-vested stock option covering 1,574 shares of common stock, as disclosed in a Form 4 filed on 2 July 2025. The option carries an exercise price of $32.86 and an expiration date of 30 June 2030. The transaction was coded �A,� indicating an issuer-awarded grant rather than an open-market purchase. No non-derivative transactions or additional derivative movements were reported.

Following this grant, Mr. Blizard directly owns 1,574 derivative securities and reported no other holdings in SNWV common stock. Because the options were already fully vested at issuance, they are immediately exercisable, potentially aligning the director’s incentives with shareholder value creation. However, the filing does not specify any accompanying cash outlay or further equity activity.

Il 30 giugno 2025, SANUWAVE Health, Inc. (simbolo: SNWV) ha concesso al Direttore Jeffrey Blizard un'opzione su azioni completamente maturata per 1.574 azioni ordinarie, come riportato in un Modulo 4 depositato il 2 luglio 2025. L'opzione ha un prezzo di esercizio di 32,86 $ e una scadenza fissata al 30 giugno 2030. La transazione è stata codificata come �A�, indicando una concessione da parte dell'emittente e non un acquisto sul mercato aperto. Non sono state segnalate altre transazioni non derivative o movimenti derivati aggiuntivi.

Dopo questa concessione, il Sig. Blizard detiene direttamente 1.574 strumenti derivati e non ha dichiarato altri titoli ordinari SNWV. Poiché le opzioni erano già completamente maturate al momento dell'emissione, sono immediatamente esercitabili, potenzialmente allineando gli incentivi del direttore con la creazione di valore per gli azionisti. Tuttavia, il documento non specifica alcun esborso in contanti o ulteriori attività azionarie.

El 30 de junio de 2025, SANUWAVE Health, Inc. (símbolo: SNWV) otorgó al Director Jeffrey Blizard una opción sobre acciones totalmente consolidada para 1,574 acciones ordinarias, según se reveló en un Formulario 4 presentado el 2 de julio de 2025. La opción tiene un precio de ejercicio de 32,86 $ y una fecha de vencimiento el 30 de junio de 2030. La transacción fue codificada como �A�, lo que indica una concesión otorgada por el emisor y no una compra en el mercado abierto. No se reportaron transacciones no derivadas ni movimientos adicionales derivados.

Tras esta concesión, el Sr. Blizard posee directamente 1,574 valores derivados y no informó otras participaciones en acciones ordinarias de SNWV. Dado que las opciones ya estaban totalmente consolidadas al momento de la emisión, son ejercitables de inmediato, lo que podría alinear los incentivos del director con la creación de valor para los accionistas. Sin embargo, la presentación no especifica ningún desembolso en efectivo ni actividad adicional de capital.

2025� 6� 30�, SANUWAVE Health, Inc. (티커: SNWV)� 이사� Jeffrey Blizard에게 1,574�� 보통주에 대� 완전 취득� 스톡 옵션� 부여했으며, 이는 2025� 7� 2� 제출� Form 4에서 공개되었습니�. � 옵션� 행사가격은 32.86달러이고, 만료일은 2030� 6� 30�입니�. 거래� 발행자가 부여한 보조금임� 나타내는 �A� 코드� 분류되었으며, 공개 시장에서� 구매가 아닙니다. 비파� 거래� 추가 파생 이동은 보고되지 않았습니�.

� 부� 이후 Blizard 이사� 직접적으� 1,574개의 파생 증권� 보유하고 있으�, SNWV 보통주에 대� 다른 보유 내역은 보고하지 않았습니�. 옵션� 발행 시점� 이미 완전� 취득� 상태였� 때문� 즉시 행사� � 있어, 이사� 인센티브가 주주 가� 창출� 일치� 가능성� 있습니다. 다만, 제출 서류에는 현금 지출이� 추가 주식 활동� 대� 명시가 없습니다.

Le 30 juin 2025, SANUWAVE Health, Inc. (symbole : SNWV) a accordé au Directeur Jeffrey Blizard une option d'achat d'actions entièrement acquise portant sur 1 574 actions ordinaires, comme révélé dans un formulaire 4 déposé le 2 juillet 2025. L'option comporte un prix d'exercice de 32,86 $ et une date d'expiration au 30 juin 2030. La transaction a été codée « A », indiquant une attribution par l'émetteur plutôt qu'un achat sur le marché ouvert. Aucune transaction non dérivée ni mouvement dérivé supplémentaire n'a été signalé.

Suite à cette attribution, M. Blizard détient directement 1 574 titres dérivés et n'a déclaré aucune autre détention d'actions ordinaires SNWV. Étant donné que les options étaient déjà entièrement acquises à leur émission, elles sont immédiatement exerçables, ce qui pourrait aligner les incitations du directeur avec la création de valeur pour les actionnaires. Toutefois, le dépôt ne précise aucun décaissement en espèces ni autre activité en actions.

Am 30. Juni 2025 gewährte SANUWAVE Health, Inc. (Ticker: SNWV) dem Direktor Jeffrey Blizard eine vollständig unverfallbare Aktienoption über 1.574 Stammaktien, wie in einem am 2. Juli 2025 eingereichten Formular 4 offengelegt wurde. Die Option hat einen Ausübungspreis von 32,86 $ und ein Ablaufdatum zum 30. Juni 2030. Die Transaktion wurde mit �A� codiert, was auf eine vom Emittenten gewährte Zuteilung und keinen Kauf am offenen Markt hinweist. Es wurden keine nicht-derivativen Transaktionen oder zusätzlichen derivativen Bewegungen gemeldet.

Nach dieser Zuteilung besitzt Herr Blizard direkt 1.574 derivative Wertpapiere und meldete keine weiteren Bestände an SNWV-Stammaktien. Da die Optionen bei Ausgabe bereits vollständig unverfallbar waren, sind sie sofort ausübbar, was die Anreize des Direktors potenziell mit der Wertschöpfung für die Aktionäre in Einklang bringt. Die Meldung gibt jedoch keine Angaben zu einer begleitenden Barzahlung oder weiteren Eigenkapitalaktivitäten.

Positive
  • None.
Negative
  • None.

Insights

TL;DR – Routine director option grant; negligible immediate impact on valuation.

The Form 4 shows a standard equity incentive: 1,574 fully-vested options to Director Jeffrey Blizard at a $32.86 strike, expiring in 2030. No common-stock sales or purchases occurred. The modest size suggests minimal dilution and limited near-term financial effect. While the grant marginally strengthens pay-for-performance alignment, it is too small to materially move SNWV’s capital structure or governance profile. Overall impact on investors is neutral.

Il 30 giugno 2025, SANUWAVE Health, Inc. (simbolo: SNWV) ha concesso al Direttore Jeffrey Blizard un'opzione su azioni completamente maturata per 1.574 azioni ordinarie, come riportato in un Modulo 4 depositato il 2 luglio 2025. L'opzione ha un prezzo di esercizio di 32,86 $ e una scadenza fissata al 30 giugno 2030. La transazione è stata codificata come �A�, indicando una concessione da parte dell'emittente e non un acquisto sul mercato aperto. Non sono state segnalate altre transazioni non derivative o movimenti derivati aggiuntivi.

Dopo questa concessione, il Sig. Blizard detiene direttamente 1.574 strumenti derivati e non ha dichiarato altri titoli ordinari SNWV. Poiché le opzioni erano già completamente maturate al momento dell'emissione, sono immediatamente esercitabili, potenzialmente allineando gli incentivi del direttore con la creazione di valore per gli azionisti. Tuttavia, il documento non specifica alcun esborso in contanti o ulteriori attività azionarie.

El 30 de junio de 2025, SANUWAVE Health, Inc. (símbolo: SNWV) otorgó al Director Jeffrey Blizard una opción sobre acciones totalmente consolidada para 1,574 acciones ordinarias, según se reveló en un Formulario 4 presentado el 2 de julio de 2025. La opción tiene un precio de ejercicio de 32,86 $ y una fecha de vencimiento el 30 de junio de 2030. La transacción fue codificada como �A�, lo que indica una concesión otorgada por el emisor y no una compra en el mercado abierto. No se reportaron transacciones no derivadas ni movimientos adicionales derivados.

Tras esta concesión, el Sr. Blizard posee directamente 1,574 valores derivados y no informó otras participaciones en acciones ordinarias de SNWV. Dado que las opciones ya estaban totalmente consolidadas al momento de la emisión, son ejercitables de inmediato, lo que podría alinear los incentivos del director con la creación de valor para los accionistas. Sin embargo, la presentación no especifica ningún desembolso en efectivo ni actividad adicional de capital.

2025� 6� 30�, SANUWAVE Health, Inc. (티커: SNWV)� 이사� Jeffrey Blizard에게 1,574�� 보통주에 대� 완전 취득� 스톡 옵션� 부여했으며, 이는 2025� 7� 2� 제출� Form 4에서 공개되었습니�. � 옵션� 행사가격은 32.86달러이고, 만료일은 2030� 6� 30�입니�. 거래� 발행자가 부여한 보조금임� 나타내는 �A� 코드� 분류되었으며, 공개 시장에서� 구매가 아닙니다. 비파� 거래� 추가 파생 이동은 보고되지 않았습니�.

� 부� 이후 Blizard 이사� 직접적으� 1,574개의 파생 증권� 보유하고 있으�, SNWV 보통주에 대� 다른 보유 내역은 보고하지 않았습니�. 옵션� 발행 시점� 이미 완전� 취득� 상태였� 때문� 즉시 행사� � 있어, 이사� 인센티브가 주주 가� 창출� 일치� 가능성� 있습니다. 다만, 제출 서류에는 현금 지출이� 추가 주식 활동� 대� 명시가 없습니다.

Le 30 juin 2025, SANUWAVE Health, Inc. (symbole : SNWV) a accordé au Directeur Jeffrey Blizard une option d'achat d'actions entièrement acquise portant sur 1 574 actions ordinaires, comme révélé dans un formulaire 4 déposé le 2 juillet 2025. L'option comporte un prix d'exercice de 32,86 $ et une date d'expiration au 30 juin 2030. La transaction a été codée « A », indiquant une attribution par l'émetteur plutôt qu'un achat sur le marché ouvert. Aucune transaction non dérivée ni mouvement dérivé supplémentaire n'a été signalé.

Suite à cette attribution, M. Blizard détient directement 1 574 titres dérivés et n'a déclaré aucune autre détention d'actions ordinaires SNWV. Étant donné que les options étaient déjà entièrement acquises à leur émission, elles sont immédiatement exerçables, ce qui pourrait aligner les incitations du directeur avec la création de valeur pour les actionnaires. Toutefois, le dépôt ne précise aucun décaissement en espèces ni autre activité en actions.

Am 30. Juni 2025 gewährte SANUWAVE Health, Inc. (Ticker: SNWV) dem Direktor Jeffrey Blizard eine vollständig unverfallbare Aktienoption über 1.574 Stammaktien, wie in einem am 2. Juli 2025 eingereichten Formular 4 offengelegt wurde. Die Option hat einen Ausübungspreis von 32,86 $ und ein Ablaufdatum zum 30. Juni 2030. Die Transaktion wurde mit �A� codiert, was auf eine vom Emittenten gewährte Zuteilung und keinen Kauf am offenen Markt hinweist. Es wurden keine nicht-derivativen Transaktionen oder zusätzlichen derivativen Bewegungen gemeldet.

Nach dieser Zuteilung besitzt Herr Blizard direkt 1.574 derivative Wertpapiere und meldete keine weiteren Bestände an SNWV-Stammaktien. Da die Optionen bei Ausgabe bereits vollständig unverfallbar waren, sind sie sofort ausübbar, was die Anreize des Direktors potenziell mit der Wertschöpfung für die Aktionäre in Einklang bringt. Die Meldung gibt jedoch keine Angaben zu einer begleitenden Barzahlung oder weiteren Eigenkapitalaktivitäten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Blizard Jeffrey

(Last) (First) (Middle)
11495 VALLEY VIEW ROAD

(Street)
EDEN PRAIRIE MN 55344

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SANUWAVE Health, Inc. [ SNWV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $32.86 06/30/2025 A 1,574 (1) 06/30/2030 Common Stock 1,574 $0 1,574 D
Explanation of Responses:
1. Options were fully vested at the grant date.
/s/ Griffin D. Foster, Attorney-in-Fact for Jeffrey Blizard 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Sanuwave Health

NASDAQ:SNWV

SNWV Rankings

SNWV Latest News

SNWV Latest SEC Filings

SNWV Stock Data

310.55M
8.09M
5.57%
35.71%
5.37%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
SUWANEE